Ulcerative Colitis Market Explore Growth and Analysis By Top Players AbbVie Inc., Hospira, Celltrion Healthcare, Johnson and Johnson, F. Hoffmann-La Roche AG, Warner Chilcott, Janssen Pharmaceuticals Inc. 

According to the study of CCFA, industrialized countries have highest incidence rate for ulcerative colitis. This disease is most prevalent in urban areas than in rural areas, also it can affect to any age group of people but most cases diagnosed are of the age in between 15 to 35. According the stats of World Gastroenterology Organization (WGO), there is rising incidence rate in emerging economies such as India. Due to changing diet and lifestyle pattern, the emerging economies will show high growth rate in incidence rate of ulcerative colitis in the near future.

Download PDF Brochure of This Business Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/238

The exact cause for ulcerative colitis is unknown, though possible reasons are may be genetic factors, environmental changes, or weakened immune system. The ulcerative colitis can be prevented by simple healthy habits such as eating small meals throughout the day, staying well hydrated throughout the day, avoiding fatty foods, and limiting intake of high-fiber food.

According to data released by the Centers for Disease Control and Prevention (CDC), there are around 2.2 to 14.3 cases found per 100,000 population per year. Also, according to a study conducted in 2014 by Crohn’s & Colitis Foundation of America (CCFA), 907,000 people suffered from ulcerative colitis in the U.S. (data based on the research conducted in between 2011-2014 by CCFA)

Also, some genetically engineered drugs also used to treat ulcerative colitis. These drugs are made up of certain living organisms that help suppress the inflammation, by targeting the inflammatory proteins such as cytokines. Some genetically engineered drugs approved by the U.S. FDA for treatment of the condition are Adalimumab (Humira), Golimumab (Simponi), Infliximab (Remicade) and Vedolizumab (Entyvio). These genetically engineered drugs may show some side effects such as fever, headache, hives, low blood pressure, breathing difficulties, back pain, and stomach pain. Also, these drugs may affect the immunity power of body to fight infection.

Competitive Analysis

Some major companies playing leading role in ulcerative colitis market are AbbVie Inc., Hospira, Celltrion Healthcare, Johnson and Johnson, F. Hoffmann-La Roche AG, Warner Chilcott, Janssen Pharmaceuticals Inc. and Takeda Pharmaceuticals Company Ltd.
Some leading drugs are used to reduce inflammation and swelling and to cure ulcerative colitis are include Sulfasalazine (Azulfidine), Mesalamine (Asacol and Lialda), Balsalazide (Colazal), and Olsalazine (Dipentum), Inflectra, Remsima, Adalimumab (Humira), Infliximab (Remicade).

Request For Customization Of This Business Research Report: https://www.coherentmarketinsights.com/insight/request-customization/238

Ulcerative colitis market taxonomy:

Global Market by Drug Type
Infliximab
Golimumab
Adalimumab
Vedolizumab
Mesalamine
Budesonide
Balsazide
Global Market by Dosage Form
Parenteral
Oral

Global Market by Geography
North America
Europe
APAC
Latin America
Middle East
Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.